Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4155/fmc.15.127 http://scihub22266oqcxt.onion/10.4155/fmc.15.127 C4673908!4673908!26397018     free     free     free       Future+Med+Chem 2015 ; 7 (14): 1901-17 Nephropedia Template TP {{tp|p=26397018|t=2015. Open access chemical probes for epigenetic targets |pdf=|usr=}}{{26397018}} gab.com Text Open access chemical probes for epigenetic targets JO: Future Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=26397018 #FOAvip Background: High attrition rates in drug discovery call for new approaches to improve target validation. Academia is filling gaps, but often lacks the experience and resources of the pharmaceutical industry resulting in poorly characterized tool compounds. Discussion: The SGC has established an open access chemical probe consortium, currently encompassing ten pharmaceutical companies. One of its mandates is to create well-characterized inhibitors (chemical probes) for epigenetic targets to enable new biology and target validation for drug development. Conclusion: Epigenetic probe compounds have proven to be very valuable and have not only spurred a plethora of novel biological findings, but also provided starting points for clinical trials. These probes have proven to be critical complementation to traditional genetic targeting strategies and provided sometimes surprising results. Twit Text FOAVip Open access chemical probes for epigenetic targets ????Future Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=26397018 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26397018 #FOAvip English Wikipedia <ref>{{Cite pmid|26397018}}</ref> Open access chemical probes for epigenetic targets #MMPMID26397018 Brown PJ; Müller S Future Med Chem 2015[Sep]; 7 (14): 1901-17 PMID26397018show ga Background: High attrition rates in drug discovery call for new approaches to improve target validation. Academia is filling gaps, but often lacks the experience and resources of the pharmaceutical industry resulting in poorly characterized tool compounds. Discussion: The SGC has established an open access chemical probe consortium, currently encompassing ten pharmaceutical companies. One of its mandates is to create well-characterized inhibitors (chemical probes) for epigenetic targets to enable new biology and target validation for drug development. Conclusion: Epigenetic probe compounds have proven to be very valuable and have not only spurred a plethora of novel biological findings, but also provided starting points for clinical trials. These probes have proven to be critical complementation to traditional genetic targeting strategies and provided sometimes surprising results. äOpen access chemical probes for epigenetic targets (epmc).pdf DeepDyve Pubget Overpricing